Embla Medical hf (OCSE:EMBLA) EBIT: kr846 Mil (TTM As of Mar. 2026)


OCSE:EMBLA Embla Medical hf OCSE:EMBLA
92 GF Score
Price kr26.40
GF Value kr34.34
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Embla Medical hf EBIT?

Embla Medical hf OCSE:EMBLA 92 EBIT is kr846 Mil as of Mar. 2026. GuruFocus rates OCSE:EMBLA with a GF Score™ of 92/100 and a GF Value™ of kr34.34 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Embla Medical hf's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr154 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr846 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Embla Medical hf's annualized ROC % for the quarter that ended in Mar. 2026 was 4.44%. Embla Medical hf's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 24.09%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Embla Medical hf's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.92%.


Embla Medical hf  (OCSE:EMBLA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Embla Medical hf's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=585.496 * ( 1 - 23.49% )/( (9994.8 + 10188.368)/ 2 )
=447.9629896/10091.584
=4.44 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11037.764 - 389.133 - ( 653.831 - max(0, 1974.568 - 2921.294+653.831))
=9994.8

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11049.812 - 359.917 - ( 610.376 - max(0, 2412.119 - 2913.646+610.376))
=10188.368

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Embla Medical hf's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=616.092/( ( (1548.216 + max(904.558, 0)) + (1547.314 + max(1114.677, 0)) )/ 2 )
=616.092/( ( 2452.774 + 2661.991 )/ 2 )
=616.092/2557.3825
=24.09 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(923.471 + 1056.371 + 287.621) - (389.133 + 0 + 973.772)
=904.558

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(909.235 + 1075.975 + 318.06) - (359.917 + 0 + 828.676)
=1114.677

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Embla Medical hf's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=845.95/14298.019
=5.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Embla Medical hf EBIT Related Terms


Embla Medical hf EBIT Historical Data

* Premium members only.

The historical data trend for Embla Medical hf's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Embla Medical hf EBIT Chart

Embla Medical hf Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 634.66 473.18 642.24 810.57 812.99

Embla Medical hf Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 144.26 211.78 255.75 224.39 154.02

OCSE:EMBLA vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Embla Medical hf's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Embla Medical hf EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Embla Medical hf's EV-to-EBIT falls into.


OCSE:EMBLA
92GF Score
Embla Medical hf OCSE:EMBLA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Embla Medical hf EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr846 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr846 Mil mean?
Embla Medical hf (OCSE:EMBLA) has a EBIT of kr846 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Embla Medical hf.
Is Embla Medical hf's EBIT too high?
Embla Medical hf's current EBIT is kr846 Mil. Overall, Embla Medical hf has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's EBIT compare to ABT and SYK?
Embla Medical hf's EBIT of kr846 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Embla Medical hf. Embla Medical hf's current EBIT is kr846 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Based on GuruFocus' analysis, Embla Medical hf (OCSE:EMBLA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr34.34, compared to a current price of kr26.40 — trading 23.1% below its estimated fair value. The current EBIT is kr846 Mil. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Embla Medical hf (OCSE:EMBLA), the current EBIT is kr846 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Embla Medical hf (OCSE:EMBLA) Overvalued in 2026?

Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued. The current stock price of kr26.40 is trading 23.1% below its estimated GF Value™ of kr34.34. GuruFocus considers Embla Medical hf to be Modestly Undervalued.

Key valuation signals for OCSE:EMBLA:

  • EBIT: kr846 Mil
  • GF Value™: kr34.34 vs. price of kr26.40 (23.1% below fair value)
  • GF Score™: 92/100 with 2 warning signs

No single metric tells the full story. See the OCSE:EMBLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Embla Medical hf Business Description

Other Exchanges 0FIW:UK5IQ:Germany
Address Grjothals 5, Reykjavik, ISL
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score

Get the complete analysis for OCSE:EMBLA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr26.40
Price
kr34.34
GF Value